Theranexus : Résultats FY sans surprise, confirmation du développement de Batten-1
>Visibilité financière jusqu’à fin T1 2024 au moins - La société publie une perte opérationnelle de 6.3 M€ en 2022 vs 9.5 M€ en 2021. La différence s’explique par des produits d’exploitation en progression à 1.2 M€ en 2022 vs 0 M€ l’année dernière. Ceux-ci proviennent principalement de subventions dans le cadre de la plateforme de recherche Neurolead. Les charges d’exploitation sont bien maitrisées : 7.5 M€ en 2022 vs 9.5 M€ l’année dernière. Theranexus disposait...Theranexus SA is a France-based company engaged in the healthcare industry. The Company is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The Company's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.